Biodexa Pharmaceuticals (BDRX) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on innovative treatments for diseases with unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, type 1 diabetes, and rare/orphan brain cancers.

• Lead assets include eRapa (proprietary rapamycin formulation), tolimidone (lyn kinase activator), and MTX110 (panobinostat formulation for brain cancers).

• eRapa has received FDA fast track designation and significant grant funding for Phase 3 trials.

• Proprietary drug delivery platforms (Q-Sphera, MidaSolve, MidaCore) support clinical assets, though no active R&D programs are ongoing for these technologies.

Financial performance and metrics

• Financial statements are prepared in accordance with IFRS and presented in British pounds sterling.

• As of September 25, 2025, public float was approximately $5.45 million, with 61,952,306,157 ordinary shares held by non-affiliates.

• The company has not offered securities under General Instruction I.B.5 of Form F-3 in the prior 12 months.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including clinical and preclinical program development, R&D, acquisitions, working capital, and capital expenditures.

• Management has broad discretion over allocation of proceeds; specific amounts and timing are not predetermined.